Medindia
Medindia LOGIN REGISTER
Advertisement

Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument

Thursday, February 12, 2009 General News
Advertisement
ABBOTT PARK, Ill., Feb. 11 Abbott (NYSE: ABT)today announced it received 510(k) clearance from the U.S. Food and DrugAdministration (FDA) for its new, compact hematology instrument, CELL-DYNEmerald(TM). Abbott's CELL-DYN Emerald will expand the company's hematologyplatform by offering a high performance, affordable solution for small to mid-sized clinical laboratories.
Advertisement

As small to mid-sized hospital laboratories and clinics continue to seekgreater efficiency and productivity under tighter space limitations, Emerald'ssmall size, touch screen software, and reliability offer an easy-to-use,compact table/bench top instrument for performing complete blood counts(CBCs), a test routinely ordered by doctors to assess a patient's overallhealth and to screen for a variety of disorders such as anemia and infection.
Advertisement

This new hematology system has many automation features designed to savelaboratories' time, allowing them to improve productivity and reduce costs.Time saving features of Abbott's CELL-DYN Emerald include:

A key facet of CELL-DYN Emerald is its compact size -- weighing just 9kg(< 20 lbs) -- as well as its intuitive software interface that allows for easynavigation and quick results. With Abbott's Emerald, CBC results are completedin 60 seconds and reported in an easy-to-read format with histogramsrepresenting white blood cells, red blood cells and platelets.

"As hospitals and clinics try to do more, faster and in less space,Abbott's CELL-DYN Emerald offers a compact, fast, reliable analyzer to supportthe hematology testing needs of many small to medium-sized hospitallaboratories and clinics," said Mike Warmuth, senior vice president,diagnostics, Abbott.

About CELL-DYN

Abbott's CELL-DYN Emerald joins the company's full line of automatedhematology instruments including: CELL-DYN Sapphire(R), CELL-DYN Ruby(R),CELL-DYN(R) 3700, CELL-DYN(R) 3200 and CELL-DYN(R) 1800.

Abbott's CELL-DYN instruments are well known for their efficiency andability to provide fast access to patient results. Instruments range fromlarger analyzers that process a high number of patient samples to smallerinstruments designed for medium and small-volume facilities.

Besides supplying standard CBC results, some instruments have additionalfeatures to aid in the evaluation of more complex disease states or infectionsincluding cancer, HIV and a variety of anemias.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad rangeof innovative instrument systems and tests for hospitals, reference labs,molecular labs, blood banks, physician offices and clinics. With more than65,000 institutional customers in more than 100 countries, Abbott's diagnosticproducts offer customers automation, convenience, bedside testing, costeffectiveness and flexibility. Abbott has helped transform the practice ofmedical diagnosis from an art to a science through the company's commitment toimproving patient care and lowering costs. The history of Abbott is filledwith examples of first-of-a-kind diagnostic products and significanttechnological and research advancements.

About Abbott

Abbott is a global, broad-based health care company devoted to thediscovery, development, manufacture and marketing of pharmaceuticals andmedical products, including nutritionals, devices and diagnostics. The companyemploys approximately 69,000 people and markets its products in more than 130countries.

Abbott's news releases and other information are available on thecompany's Web site at http://www.abbott.com.-- A full touch-screen monitor to simplify operation. -- One-button startup. -- Low reagent consumption. -- Automatic cleaning and shutdown features. -- Barcode labeled reagents.

SOURCE Abbott
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close